Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 165 for “"Infliximab"”.
-
Monitorización de niveles de Infliximab y anticuerpos Anti-Infliximab en pacientes con enfermedad inflamatoria intestinal en práctica clínica
Introducción Infliximab (IFX) es un fármaco anti-TNF que consigue una buena tasa de respuesta y remisión en muchos pacientes con enfermedad inflamatoria intestinal (EII). No obstante, entre el 30-40% de los pacientes tratados con IFX pierden la respuesta durante el periodo de mantenimiento del …
-
ANTIBODIES TO INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: CLINICAL AND MOLECULAR TARGETS
Infliximab was the first biological therapy to be approved for use in inflammatory bowel disease (IBD). Similar to other biological therapies, secondary loss of response to infliximab occurs in up to 50% of patients at 1 year follow up. In the case of infliximab, antibodies to infliximab (ATI) are …
-
Η συμβολή του Infliximab (anti-TNFa) ως αντιουλωτικού παράγοντα στην επέμβαση του γλαυκώματος
… in clotting, inflammation and apoptosis. Infliximab is a chimeric monoclonal antibody that binds to both soluble and transmembrane proinflammatory cytokine TNF-α. We hypothesized that blocking TNF-a with Infliximab would reduce both inflammation and fibrosis post glaucoma filtration …
-
Untersuchungen zu Wirkungen von TNF á und des TNF á Blockers Infliximab auf Immunzellen
… Die anti TNF α Behandlung mit Biologika wie Infliximab (Ifx), einem monoklonalen chimären Antikörper, reduzieren die Krankheitsaktivität bei Patienten mit RA, M. Crohn und anderen Autoimmunerkrankungen. Infliximab blockiert nicht nur lösliches TNF α (sTNF α), sondern bindet auch an das auf …
-
The Effectiveness of Leflunomide Etanercept and Infliximab in the Treatment of Rheumatoid Arthritis:a systematic review
… target TNF-α, such as etanercept (Enbrel®) and infliximab (Remicade®), and leflunomide (Arava®) that targets proliferating T-cells offer a novel approach. With the approval of marketing these drugs by the Food and Drug Administration (FDA), the safety and efficacy data for these new disease …
-
Análisis costo versus efectividad del Etanercept, Infliximab y Adalimumab, en pacientes con artritis reumatoide refractaria
Currently there are several technologies to treat rheumatoid arthritis (RA), which has become an industry since the treatments for it can be for long periods of time, with significant costs for the Colombian health system. Health institutions face a major challenge in trying to improve the quality …
-
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
… with the monclonal anti-TNFa antibody infliximab is clinically highly effective. The precise mechanism of action, however, is not known. I investigated the cytokine response in 20 active AS patients during infliximab therapy. The results indicated that infliximab could downregulate the …
-
Serum and fecal biomarkers predict response to Infliximab therapy in pediatric patients with inflammatory bowel disease
… IC after being treated with the anti-TNF therapy Infliximab (Remicade). The second objective is to study the relationship between changes in these biomarker levels and the clinical, biochemical, and endoscopic outcome parameters of IBD in patients. This is a multicenter, longitudinal, cohort study …
-
Effect of infliximab therapy on serum and fecal biomarker levels in pediatric patients with inflammatory bowel disease
… and adolescents with CD, UC, and IC initiating infliximab therapy while investigating any parallels between fluctuations in biomarker levels and endoscopic, clinical, and biochemical outcomes. The inflammatory biomarkers evaluated in this study include fecal and serum …
-
Implementation of high-dose interval vitamin D supplementation in patients with inflammatory bowel disease receiving infliximab or vedolizumab
… years of age, who received regularly scheduled infliximab or vedolizumab infusions, and had serum 25-OHD levels below 30 ng/mL were recruited for the study. These patients were screened for the exclusion criteria, including underlying liver or kidney disease. Enrolled participants were given …
-
Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte
Einleitung: Das Infliximab Biosimilar CT-P13 wurde 2013 von der EMA im Rahmen eines Extrapolationsprozesses für die Behandlung von chronisch entzündlichen Darmerkrankungen (CED) ohne Zulassungsstudien genehmigt. Seither zeigten mehrere unkontrollierte Studien, dass CT-P13 sicher und effektiv ist, …
-
Effects of Infliximab Therapy on Hospitalization, Surgery and Healthcare Consumption in Crohn’s Disease: A Population Based Propensity Score Matched Analysis
… Quebec, Canada, to estimate the effectiveness of infliximab therapy in reducing CD-related surgery, hospitalization and health care resource consumption in subjects with CD. Methods : We obtained patient level prescription data, physician billing claims and hospitalization data from the Régie de …
-
Implementation of high-dose oral vitamin D therapy in pediatric patients with inflammatory bowel disease receiving infliximab or vedolizumab infusions
… further limited to patients being treated with infliximab or vedolizumab. Patients received eight or nine doses of vitamin D during the study. Data was collected at various points, including survey responses, serum 25-OHD levels, and safety labs. RESULTS: Serum 25-OHD levels increased …
-
Μελέτη της επίδρασης της θεραπείας με anti-TNF στην επούλωση της εντερικής αναστόμωσης
… aim of the study was to evaluate the effect of Infliximab on intestinal anastomosis healing. Methods Fifty six wistar rats were divided into 4 groups: (a) 20 rats were subjected to excision of part of the terminal ileum followed by anastomosis which was evaluated on the 3rd or 7th postoperative …
-
Μελέτη της θεραπείας με ανοσοτροποιητικά φάρμακα και βιολογικούς παράγοντες σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων
Introduction: Therapeutic monitoring of infliximab correlates with improved outcomes in patients with inflammatory bowel diseases (IBD). This cross-sectional study aimed to assess the relationship between serum infliximab trough levels (TLs), antibodies-to-infliximab (ATI) and therapeutic outcomes …
-
LA RIDUZIONE DEI MACROFAGI CD68+ TISSUTALI E LA DIMINUZIONE NELL'ESPRESSIONE MUCOSALE DI INTERLEUCHINA 17 SONO STRETTAMENTE CORRELATI CON LA RISPOSTA ENDOSCOPICA E CON LA GUARIGIONE DELLA MUCOSA A SEGUITO DI TERAPIA CON INFLIXIMAB IN PAZIENTI CON MALATTIE INFIAMMATORIE CRONICHE INTESTINALI
… successful results, the exact mechanism by which infliximab suppresses intestinal inflammation is still a matter of debate. In this study, we used a translational approach to identify the key mechanisms associated with resolution of mucosal inflammation induced by infliximab. Methods: A total of …
-
Optimisation of Medical Therapy for Perianal Fistulising Crohn’s Disease
… of life. The anti-tumour necrosis alpha agents (infliximab and adalimumab) are the mainstay of therapy, however the optimal drug levels required for fistula healing remain unclear. This Masters Project includes two similar but complementary studies that aim to determine the association between …
-
Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática
… ABP 501 (Adalimumab), Biosimilar CT-P13 (Infliximab). Methodology: A systematic review of the literature was carried out that included intervention studies, evaluating the clinical responses according to the ACR20, ACR50, ACR 70, DAS 28 PCR, and safety scales evaluated by the formation of …
-
Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.
… Europea (EMA) aprobó el primer biosimilar del Infliximab (CT-P13) con las mismas indicaciones del medicamento de referencia, basados en los análisis obtenidos de dos estudios realizados en pacientes con enfermedades reumatológicas. Esta extrapolación de resultados, así como la sustitución del …
Page 1 of 9